VRDN Stock Analysis: Viridian Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.142m USD | 12M Return: 28.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.2M
Qual. Beats: 0
Rev. Trend: 67.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a U.S.-based clinical-stage biotechnology company headquartered in Waltham, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and rare diseases. The company was originally incorporated in 2010 as Miragen Therapeutics, Inc. and rebranded under its current name in January 2021.
Its pipeline centers on thyroid eye disease (TED), led by two differentiated IGF-1R antibodies: Veligrotrug, an intravenously administered humanized monoclonal antibody, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R therapy. Viridian is also advancing an anti-TSHR candidate for Graves disease and TED, along with engineered neonatal Fc receptor (FcRn) inhibitors-VRDN-006, a selective Fc fragment, and VRDN-008, a half-life-extended bispecific FcRn inhibitor designed to prolong IgG suppression.
As a small-cap biotechnology company, Viridian operates a typical clinical-stage biotech business model, prioritizing R&D investment and pipeline advancement over near-term commercial revenue generation. The company is listed on NASDAQ and is classified within the Health Care sectors Biotechnology sub-industry.
- Veligrotrug approval timing drives near-term stock catalyst
- Tepezza competition limits TED market share opportunity
- Cash burn and dilution risk fund FcRn pipeline advancement
| Net Income: -360.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA 2.78 > 1.0 |
| NWC/Revenue: 1.03k% < 20% (prev 206k%; Δ -205k% < -1%) |
| CFO/TA -0.38 > 3% & CFO -303.4m > Net Income -360.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.2m) vs 12m ago 25.65% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 9.78% > 50% (prev 0.05%; Δ 9.74% > 0%) |
| Interest Coverage Ratio: -31.36 > 6 (EBIT TTM -349.4m / Interest Expense TTM 11.1m) |
| A: 0.93 (Total Current Assets 784.7m - Total Current Liabilities 51.8m) / Total Assets 789.0m |
| B: -1.83 (Retained Earnings -1.44b / Total Assets 789.0m) |
| C: -0.48 (EBIT TTM -349.4m / Avg Total Assets 725.0m) |
| D: 4.16 (Book Value of Equity 636.0m / Total Liabilities 153.0m) |
| Altman-Z'' = 1.26 = BB |
As of July 08, 2026, the stock is trading at USD 20.47 with a total of 3,472,622 shares traded. Over the past week, the price has changed by +8.94%, over one month by +30.13%, over three months by +46.63% and over the past year by +28.82%.
Current recommended Stop Loss: 19.30 (which is 5.7% or 1.3 ATR below the current price).
Viridian Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy VRDN.
- StrongBuy: 9
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 36.1 | 76.5% |
P/E Forward = 1.0072
P/S = 30.2081
P/B = 4.0494
Revenue TTM = 70.9m USD
EBIT TTM = -349.4m USD
EBITDA TTM = -349.4m USD
Long Term Debt = 50.4m USD (from longTermDebt, last quarter)
Short Term Debt = 738k USD (from shortTermDebt, last quarter)
Debt = 51.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 738k
Net Debt = -635.3m USD (calculated: Debt 51.9m - CCE 687.2m)
Enterprise Value = 1.51b USD (2.14b + Debt 51.9m - CCE 687.2m)
Interest Coverage Ratio = -31.36 (Ebit TTM -349.4m / Interest Expense TTM 11.1m)
EV/FCF = -4.80x (Enterprise Value 1.51b / FCF TTM -314.1m)
FCF Yield = -20.84% (FCF TTM -314.1m / Enterprise Value 1.51b)
FCF Margin = -442.9% (FCF TTM -314.1m / Revenue TTM 70.9m)
Net Margin = -508.5% (Net Income TTM -360.6m / Revenue TTM 70.9m)
Gross Margin = unknown ((Revenue TTM 70.9m - Cost of Revenue TTM 1.16m) / Revenue TTM)
Tobins Q-Ratio = 1.91 (Enterprise Value 1.51b / Total Assets 789.0m)
Interest Expense / Debt = 21.47% (Interest Expense 11.1m / Debt 51.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -276.1m (EBIT -349.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.05 (Total Current Assets 784.7m / Total Current Liabilities 65.1m)
Debt / Equity = 0.08 (Debt 51.9m / totalStockholderEquity, last quarter 636.0m)
Debt / EBITDA = 1.82 (negative EBITDA) (Net Debt -635.3m / EBITDA -349.4m)
Debt / FCF = 2.02 (negative FCF - burning cash) (Net Debt -635.3m / FCF TTM -314.1m)
Total Stockholder Equity = 594.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.74% (Net Income -360.6m / Total Assets 789.0m)
RoE = -60.70% (Net Income TTM -360.6m / Total Stockholder Equity 594.1m)
RoCE = -54.22% (EBIT -349.4m / Capital Employed (Equity 594.1m + L.T.Debt 50.4m))
RoIC = -37.59% (negative operating profit) (NOPAT -276.1m / Invested Capital 734.4m)
WACC = 8.57% (E(2.14b)/V(2.19b) * Re(8.37%) + D(51.9m)/V(2.19b) * Rd(21.47%) * (1-Tc(0.21)))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 43.86%
[DCF] Fair Price = unknown (Cash Flow -314.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.83 | # QB: 0
Revenue Correlation: 66.96 | Revenue CAGR: 506.4% | SUE: 0.01 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.03 | Chg30d=+1.69% | Revisions=+12% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.93 | Chg30d=+5.77% | Revisions=+12% | Analysts=11
EPS current Year (2026-12-31): EPS=-3.80 | Chg30d=+0.40% | Revisions=+21% | GrowthEPS=-14.4% | GrowthRev=-61.0%
EPS next Year (2027-12-31): EPS=-2.63 | Chg30d=-4.85% | Revisions=+10% | GrowthEPS=+30.7% | GrowthRev=+737.4%
[Analyst] Revisions Ratio: +19% (up=17, down=11)